8-K: Cara Therapeutics Shifts Focus to Notalgia Paresthetica Program, Cuts Workforce and Extends Cash Runway

Cara Therapeutics is prioritizing its notalgia paresthetica program, discontinuing its chronic kidney disease program, reducing its workforce, and extending its cash runway into 2026.

Summary

• Cara Therapeutics has decided to focus its resources on the development of oral difelikefalin for notalgia paresthetica (NP), a neuropathic disorder characterized by chronic itching.
• The company is terminating its Phase 3 clinical program for oral difelikefalin in advanced chronic kidney disease (CKD), including the KICK 1 and KICK 2 trials.
• A workforce reduction of up to 50% is planned, expected to be substantially completed by January 31, 2024.
• The company anticipates incurring charges between $2.5 million and $3 million in the first quarter of 2024 related to the workforce reduction.
• Cara Therapeutics ended 2023 with approximately $101 million in cash.
• The strategic changes are expected to extend the company's cash runway into 2026.
• The Phase 2/3 clinical program for NP, known as KOURAGE, is progressing ahead of schedule.
• A data readout from the dose-finding portion of the KOURAGE program is expected in the third quarter of 2024.
• Final topline results from the first pivotal study are expected by the end of 2025, with the second study results in early 2026.
• The addressable market for NP is estimated at 650,000 patients in the U.S. who are under the care of a healthcare provider.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The strategic shift to NP and the extended cash runway are positive, but the discontinuation of the CKD program and the workforce reduction are negative. The overall sentiment is cautiously optimistic but with significant challenges.

Positives

• The company is focusing on a program with significant commercial potential, notalgia paresthetica (NP).
• The cash runway has been extended into 2026, providing financial stability for the NP program.
• The KOURAGE program is progressing ahead of schedule.
• The company has a clear timeline for data readouts and topline results for the NP program.
• The company ended 2023 with approximately $101 million in cash.

Negatives

• The company is terminating its Phase 3 clinical program for oral difelikefalin in advanced chronic kidney disease (CKD).
• A significant workforce reduction of up to 50% is planned.
• The company will incur charges of $2.5 million to $3 million in Q1 2024 related to the workforce reduction.
• Frdrique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the company.

Risks

• The company faces risks inherent in the clinical and regulatory development of pharmaceutical products.
• There are risks associated with the launch of new products, including the performance of commercial partners.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• The company's success is dependent on the successful development and commercialization of oral difelikefalin for NP.

Future Outlook

The company expects its capital resources to be sufficient to fund its currently anticipated operating plan into 2026, focusing on the development of oral difelikefalin for notalgia paresthetica.

Management Comments

• We are sharpening our clinical focus on the rapidly progressing Phase 2/3 study in NP, which we believe is the therapeutic indication with the greatest commercial potential for oral difelikefalin, said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics.
• Following careful consideration, we have decided to discontinue our work in advanced chronic kidney disease (CKD).
• Unfortunately, as a result of the difficult decision to restructure the Company, many of our talented team members will depart the organization.
• We expect the changes we are making to extend our cash runway into 2026, allowing us to reach all expected key value-inflection milestones in the NP clinical program.

Industry Context

The shift in focus to notalgia paresthetica reflects a strategic decision to prioritize a program with a clear unmet need and commercial potential, as there are currently no FDA-approved therapies for this condition. This move also aligns with a broader trend in the biotech industry to streamline operations and focus on core assets to maximize shareholder value.

Comparison to Industry Standards

• The decision to discontinue the CKD program and focus on NP is a strategic shift, similar to other biotech companies that have streamlined their pipelines to focus on core assets.
• The workforce reduction of up to 50% is a significant measure, comparable to other companies undergoing restructuring to extend their cash runway.
• The company's cash runway extension into 2026 is a positive development, providing financial stability for the NP program, which is a key focus for the company.
• The estimated addressable market of 650,000 patients in the U.S. for NP is a significant opportunity, comparable to other rare disease markets that have attracted investment and development.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term volatility due to the restructuring but could benefit from the long-term focus on NP.
• Employees will be significantly impacted by the workforce reduction.
• Patients with notalgia paresthetica may benefit from the accelerated development of oral difelikefalin.
• Patients with advanced chronic kidney disease will not benefit from the development of oral difelikefalin.

Next Steps

• The company will focus on the KOURAGE Phase 2/3 clinical program for notalgia paresthetica.
• The company will complete the workforce reduction by January 31, 2024.
• The company will provide a data readout from the dose-finding portion of the KOURAGE program in the third quarter of 2024.
• The company will release final topline results from the first pivotal study by the end of 2025 and the second study by early 2026.

Key Dates

Keywords

Notalgia Paresthetica, Oral Difelikefalin, Clinical Program, Workforce Reduction, Cash Runway, Pruritus, KOURAGE, Chronic Kidney Disease, Phase 3, Phase 2/3